The short version of melanogenesis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
The opium poppy was cultivated in lower Mesopotamia as long ago as 3400 BC. The chemical analysis of opium in the 19th century revealed that most of its activity could be ascribed to the alkaloids codeine and morphine. Diamorphine was first synthesized in 1874 by C. R. Alder Wright, an English chemist working at St. Mary's Hospital Medical School in London who had been experimenting combining morphine with various acids. He boiled anhydrous morphine alkaloid with acetic anhydride for several hours and produced a more potent, acetylated form of morphine which is now called diacetylmorphine or morphine diacetate. He sent the compound to F. M. Pierce of Owens College in Manchester for analysis. Pierce told Wright:
=== Rule of 13 === The Rule of 13 is a simple procedure for tabulating possible chemical formula for a given molecular mass. The first step in applying the rule is to assume that only carbon and hydrogen are present in the molecule and that the molecule comprises some number of CH "units" each of which has a nominal mass of 13. If the molecular weight of the molecule in question is M, the number of possible CH units is n and
2GO Group, Inc. (branded as 2GO) is a Philippine logistics and transportation company engaged in freight shipping, courier and parcel delivery, warehousing, inventory management, distribution, and passenger sea travel. It operates a fleet of ten inter-island vessels transporting cargo and passengers across domestic routes in the Philippines. The company traces its roots to William Lines, Inc., which was established on May 26, 1949. William Lines grew to become one of the largest shipping companies in the Philippines during the 1970s to the 1990s, before eventually merging with other domestic shipping firms that later formed what is now known as 2GO Group, Inc. 2GO is a subsidiary of SM Investments Corporation (SMIC), one of the country's largest conglomerates. Another principal shareholder is Trident Investments.
Sources: en.wikipedia.org
=== Charles Hanani === Charles Hanani (Adam Levy) is Yasmin's father, and the wealthy CEO of the Hanani Publishing company. Charles is a serial philanderer, long divorced from Yasmin's mother Azar. He has a strained relationship with Yasmin, whom he treats like a child, and who carries trauma from growing up around her father's sexually inappropriate behavior. Charles reenters Yasmin’s life in series 2 when he arrives in London on business. Hoping to transition into Pierpoint’s private wealth management division, Yasmin brings him on as a client, only to learn that much of his fortune has been drained by nondisclosure settlements with women he had affairs with—including her former nanny, leading Yasmin to realize he likely groomed her. When confronted, Charles attacks Yasmin for condemning him while benefiting from his wealth and cuts her off financially. In series 3, Yasmin joins Charles on his yacht in Mallorca and catches him performing oral sex on a pregnant employee. Amid revelations that he is being sued by his own company for historic embezzlement, the two engage in a vicious confrontation in which Yasmin accuses him of sexualizing her throughout her life. A drunken Charles jumps overboard after Yasmin wishes him dead, and she makes no attempt to save him; Harper helps cover up her involvement. After Charles’ body is recovered, Hanani Publishing scapegoats Yasmin to deflect from its own complicity in silencing his victims, prompting her to sue the company.
=== Recent history === An IRA bomb exploded near the railway station in March 1997, damaging signalling equipment. The original IRA message was confusing and led to the evacuation of the Wilmslow police station to the local leisure centre not far from the explosion. Nobody was hurt. In the general election of the same year, the parliamentary constituency of Tatton, in which Wilmslow falls, made headlines as part of the "sleaze" accusations levelled against the then Conservative Government. Tatton MP, Neil Hamilton, was accused of accepting cash for tabling Parliamentary questions; he was defeated subsequently in the election by independent candidate Martin Bell. Bell was supported in his door to door canvassing for votes by David Soul and served a single term as MP.
=== Post-release === The retail version included new content, such as three additional weapons designed by Minh Le and updated player models provided by Valve. Maverick Developments created a training map for the retail edition. On November 9, 2000, Valve announced that the retail version had gone gold, and the mod version was released shortly after. It was launched under the name Half-Life: Counter-Strike because according to Jess Cliffe, the game did not have a strong identity. After launch, Valve continued releasing updates. Version 1.1 implemented a new spectator mode, version 1.3 introduced voice chat, and version 1.4 added anti-cheat measures. Counter-Strike 1.5, released on June 12, 2002, was the last update before transitioning to Steam. In October 2002, it was stated that Counter-Strike 1.6 would initially be distributed via Steam, with a beta test preceding its official release. Public beta testing was originally set to begin in mid-November, but the launch was first postponed to mid-December before finally starting on January 16, 2003. On the same day, due to overwhelming demand, further beta admissions were quickly suspended as Steam's servers ran out of bandwidth. It was available to the public once again in July 2003. Along with the beta release, Valve and Plantronics announced a blue-and-gold-colored Counter-Strike headset based on Plantronics' DSP-500 headset. The headset had an adjustable microphone boom, a built-in volume control, and was usable with a USB port rather than a sound card.
One factor that has an important effect on this electrical activity of gonadotrophs is the gonadotropin-releasing hormone (GnRH). GnRH is a hormone released by the hypothalamus, and it is responsible for signaling gonadotrophs to release gonadotropins FSH and LH. GnRH binds to gonadotropin-releasing hormone receptors (GnRHR), which is a G-protein coupled receptor, and signals the oscillation of calcium that hyperpolarizes gonadotropic cell membranes. This oscillation of calcium ions occurs through the resultant signaling cascade of the GnRH binding to the GnRHR in the plasma membrane of the gonadotroph. The G-protein associated with the GnRHR is activated by the binding of GnRH, which results in increased phospholipase C (PLC) activity in the plasma membrane. PLC cleaves phosphatidylinositol-4,5-biophosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG) signals. DAG activates protein kinase C (PKC), which phosphorylates proteins, and IP3 binds to IP3 receptors on the membrane of the endoplasmic reticulum (ER). This binding results in the release of intracellular calcium ions stored within the ER. Therefore, this increase in calcium ions signals the synthesis of secretion of FSH and LH in gonadotrophs. Overall, the fluctuation of calcium levels that is activated by the electrical activity and the signaling pathway within gonadotropic cells collectively contribute to the synthesis and release of gonadotropins that will serve an endocrine function in the reproductive system.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.